A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT PEMBROLIZUMAB IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE (STAGES IB-III) NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY

被引：0
|
作者：
Draganigos, A. [1 ]
Nguyen, S. [1 ]
Skroumpelos, A. [2 ]
Iliopoulou, E. [2 ]
Mylonas, C. [2 ]
Karokis, A. [2 ]
机构：
[1] MSD Greece, Athens A1, Greece
[2] MSD Greece, Alimos, Attica, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE192
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT FOLLOWING COMPLETE RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN ADULT PATIENTS WITH EARLY-STAGE NON-SMALL CELL LUNG CANCER WITH A HIGH RISK OF RECURRENCE
    Miguel, Silva L.
    Pinheiro, B.
    Carvalho, P.
    Jovanoski, N.
    Belleli, R.
    Abogunrin, S.
    Alves, P.
    Araujo, A.
    Barata, F.
    Hespanhol, V
    da Luz, R.
    Borges, M.
    VALUE IN HEALTH, 2023, 26 (12) : S65 - S65
  • [2] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB AS ADJUVANT TREATMENT (MONOTHERAPY) FOR ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING RESECTION AND PLATINUM-BASED CHEMOTHERAPY IN GREECE
    Nomikos, N.
    Naoum, P.
    Karampli, E.
    Jovanoski, N.
    Kakouros, M.
    Sideri-Papagianni, G.
    Kyriopoulos, I
    Pavi, E.
    Athanasakis, K.
    VALUE IN HEALTH, 2023, 26 (12) : S186 - S187
  • [3] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
    Tian, Wentao
    Niu, Lishui
    Wang, Ziqi
    Lu, Ruoyu
    Xiao, Gang
    Deng, Fuxing
    Tanzhu, Guilong
    Zhou, Rongrong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [4] ADJUVANT CHEMOTHERAPY IN RESECTED STAGE IB-III NON SMALL CELL LUNG CANCER
    Zhang, B.
    Wong, H-L
    Gunawardana, D.
    Parente, P.
    de Boer, R.
    Barling, A.
    Antippa, P.
    Wong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S32 - S32
  • [5] The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.
    Hudson, Jessica Lynn
    Aung, Wint Y.
    Santos, Carlos A. Q.
    Chang, Su-Hsin
    Olsen, Margaret A.
    Meyers, Bryan F.
    Morgensztern, Daniel
    Puri, Varun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.
    Stenehjem, David D.
    Bellows, Brandon Kyle
    Kaldate, Rajesh R.
    Jones, Joshua Timothy
    Siebert, Uwe
    Brixner, Diana I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Advanced age is associated with lack of administration of adjuvant chemotherapy for completely resected stage IB-III non-small cell lung cancer (NSCLC)
    Riely, Gregory J.
    Seshan, V. E.
    Azzoli, C. G.
    Kris, Mark G.
    Rusch, Valerie W.
    Park, Bernard K.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S454 - S454
  • [8] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
  • [9] Adjuvant chemotherapy for early-stage non-small cell lung cancer
    Visbal, AL
    Leighl, NB
    Feld, R
    Shepherd, FA
    CHEST, 2005, 128 (04) : 2933 - 2943
  • [10] Adjuvant chemotherapy in early-stage non-small cell lung cancer
    Dômont, J
    Soria, JC
    Le Chevalier, T
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 279 - 283
12345